LOUISVILLE, Ky. – A biotechnology company executive, a major drug company laboratory official and a Yale University chemist will speak at a March 14 University of Louisville symposium on designing new medicines.
U of L’s Institute for Molecular Diversity and Drug Design (IMD3) is sponsor of the third annual symposium. The symposium title, “From Genomics to Therapeutics,” refers to how knowledge from the human genome project is applied to protein structures, which then are used to design and test new possibilities for medicines and treatments.
Sessions will run from 8:30 a.m. to 4:30 p.m. at Rudd Heart and Lung Conference Center at Jewish Hospital. The event is geared to scientists, students, pharmaceutical companies and research institutions.
Deadline is March 1 for the $15 registration, which includes lunch and refreshment breaks. Additional information, including speaker biographies and an online registration form, is available at: www.imd3.org.
Featured speakers will be:
- Mark Erlander, vice president of Arcturus Applied Genomics in Carlsbad, Calif.; “Molecular Signatures of Breast Cancer: Gene Expression Profiling of Laser-captured Precancerous and Cancerous Cells”; 8:50 a.m.
- Andrew Hamilton, the Irenee du Pont chemistry professor and chair at Yale University, “Towards Artificial Antibodies: Protein Surface Recognition by Synthetic Receptors,” 11 a.m.
- William Chin, vice president of gene regulation, bone and inflammation research at Lilly Research Laboratories; “Estrogen Action: New Mechanisms, New Therapies”; 1:30 p.m.
The Institute for Molecular Diversity and Drug Design is a University of Louisville organization that unites researchers from several academic areas to encourage development of disease treatments and medicines.
For more information, call institute director Arno Spatola at (502) 852-5979.